SANUWAVE Health, Inc. 8-K

What Happened
On March 13, 2026 SANUWAVE Health, Inc. (SNWV) filed an 8-K reporting that a third‑party sales and use tax nexus study identified historical state sales and use tax liabilities. After discussions with management, the audit committee and the Company’s current and former auditors (Baker Tilly US, LLP and Marcum LLP), the committee concluded certain previously issued financial statements should no longer be relied upon. The Company plans to restate its audited consolidated financial statements for the year ended December 31, 2024 in its 2025 Form 10-K and will include restated unaudited information for the affected interim periods.

Key Details

• Affected filings include the audited 2024 year-end statements and multiple quarterly Form 10-Q periods in 2024 and 2025 (Q1, Q2, Q3 and related interim filings noted in the 8-K).
• Expected balance sheet impact as of December 31, 2025: liabilities to increase by approximately $4.9 million to $5.2 million.
• Expected income statement impact: additional expense (taxes, interest, penalties) of roughly $1.6M–$1.8M for year ended Dec 31, 2024, and $1.7M–$1.9M for year ended Dec 31, 2025.
• Management is evaluating whether this issue creates additional material weaknesses in internal control over financial reporting; conclusions will be disclosed in the 2025 Form 10-K, which the Company expects to file timely.

Why It Matters
A restatement means previously released financial results for the listed periods are no longer reliable and will be revised, which can affect reported earnings, liabilities and key metrics investors use to value the company. The identified multi‑million dollar sales and use tax exposure and the potential for internal control weaknesses are material items investors should monitor. Review the upcoming 2025 Form 10-K for the finalized restated figures and management’s assessment of controls.